X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Inderal-Generic (propranolol) is a β-adrenoceptors antagonist. It is now approved for the treatment of hypertension, angina pectoris, migraine, hypertrophic subaortic stenosis.
Lead Product(s): Propranolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inderal-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2024
Details:
Propranolol hydrochloride tablet is a synthetic beta-adrenergic receptor blocking agent, which is indicated for the treatment of the management of hypertension.
Lead Product(s): Propranolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inderal-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
Pfizer Canada is recalling all lots of Inderal-LA (propranolol hydrochloride) extended release capsules, in 60 mg, 80 mg, 120 mg and 160 mg strengths, due to the presence of a nitrosamine impurity (N-nitroso-propranolol) above the acceptable level.
Lead Product(s): Propranolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inderal-LA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.
Lead Product(s): Propranolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATNAHS PHARMA UK LIMITED
Deal Size: $390.0 million Upfront Cash: $350.0 million
Deal Type: Divestment January 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
